Rowlandmiller & PARTNERS.ADV Decreases Holdings in Zoetis Inc. (NYSE:ZTS)

Rowlandmiller & PARTNERS.ADV cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,653 shares of the company’s stock after selling 120 shares during the period. Rowlandmiller & PARTNERS.ADV’s holdings in Zoetis were worth $518,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ZTS. Webster Bank N. A. increased its stake in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares in the last quarter. Quarry LP increased its stake in shares of Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares in the last quarter. LRI Investments LLC purchased a new stake in shares of Zoetis in the 1st quarter worth $43,000. Central Valley Advisors LLC purchased a new stake in shares of Zoetis in the 2nd quarter worth $49,000. Finally, Future Financial Wealth Managment LLC purchased a new stake in shares of Zoetis in the 1st quarter worth $51,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ZTS. Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research increased their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Stifel Nicolaus increased their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. increased their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $221.44.

Zoetis Stock Performance

Shares of ZTS stock opened at $181.52 on Friday. The firm has a market cap of $82.24 billion, a price-to-earnings ratio of 35.52, a PEG ratio of 2.94 and a beta of 0.89. The company’s 50 day moving average is $189.23 and its 200 day moving average is $177.58. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the firm earned $1.41 earnings per share. On average, sell-side analysts anticipate that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.95%. Zoetis’s dividend payout ratio (DPR) is 33.86%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.